基因毒性测试指南数据的可变性和不确定性:我们知道什么,为什么这很重要
Giuseppa Raitano1, Tessa E Pronk2, Chiara L Battistelli3
1Department of Environmental Health Sciences, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy.
Archives of toxicology
|February 16, 2026
概括
基因毒性测试数据显示出显著的变异性,影响了非动物方法 (NAM) 的整合. 了解这种数据不确定性对于在监管性基因毒性评估中验证NAM至关重要.
科学领域:
- 毒理学 毒理学 毒理学
- 监管科学 监管科学
- 计算生物学 计算生物学
背景情况:
- 基因毒性测试指南 (TG) 已经发展,导致数据库中的数据异质.
- 在主要数据库 (ECVAM,ISSMIC,OASIS) 的基因毒性调用中存在显著的变化.
研究的目的:
- 检查符合试验指南的基因毒性数据中的变异性和不确定性.
- 探索将非动物方法 (NAM) 整合到监管框架中的影响.
- 提出NAM开发和验证方面的考虑.
主要方法:
- 审查经合组织测试指南的历史修订.
- 对主要的基因毒性数据库 (ECVAM,ISSMIC,OASIS) 的分析.
- 对EFSA基因毒性数据库的统计分析,以确定解释变异性的因素.
主要成果:
- 在数据库中观察到基因毒性呼叫的实质性变异.
- 22-77%的化合物在EFSA数据库中显示复制结果相似度低于85%.
- 确定解释变量的关键变量受到实际约束的限制,这表明基线不确定性.
结论:
- 在评估NAM性能时,必须考虑参考数据的内在变异性和不确定性.
- 基于NAM的综合测试和评估方法 (IATA) 应该明确地解决数据的变化.
- 这一审查为提高NAM在基因毒性评估中的接受度和实用性提供了基础.
相关概念视频
Mutagenicity and Carcinogenicity
2.0K
Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...
2.0K
Toxicity Testing in Animals
23
Toxicity tests in animals are grounded on two main assumptions: first, the effects observed in laboratory animals can be extrapolated to humans, especially when adjusted for body surface area; second, high-dose exposure in animals is essential to identify potential human hazards from lower doses. This is based on the quantal dose-response concept, which faces the challenge of extrapolating results from relatively few test animals to much larger human populations. For example, a 0.01% incidence...
23
Drug toxicity: Idiosyncratic Reactions
31
Idiosyncratic drug reactions represent abnormal chemical responses that vary significantly among individuals, ranging from extreme sensitivity to low doses to insensitivity to high doses. These reactions often occur due to the drug's covalent binding with serum proteins, forming a foreign hapten that triggers an immunotoxicological response. The variability in drug reactions has a strong pharmacogenetic foundation, with genetic differences crucial in how individuals metabolize drugs. For...
31
Data Validation
2.6K
Method validation is a crucial process in analytical chemistry designed to confirm that a given method consistently produces reliable and high-quality results. This process is essential when a method is applied to different sample matrices or when procedural modifications are made, ensuring that the results meet acceptable standards across various applications.
Key parameters for method validation include:
Key parameters for method validation include:
2.6K
Principles of Pharmacogenetics: Types of Genetic Variants
14
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
14
Mutation, Gene Flow, and Genetic Drift
64.7K
In a population that is not at Hardy-Weinberg equilibrium, the frequency of alleles changes over time. Therefore, any deviations from the five conditions of Hardy-Weinberg equilibrium can alter the genetic variation of a given population. Conditions that change the genetic variability of a population include mutations, natural selection, non-random mating, gene flow, and genetic drift (small population size).
64.7K


